23,622 Shares in Rein Therapeutics Inc. $RNTX Bought by Blair William & Co. IL

Blair William & Co. IL bought a new position in Rein Therapeutics Inc. (NASDAQ:RNTX) during the second quarter, according to its most recent filing with the SEC. The firm bought 23,622 shares of the company’s stock, valued at approximately $33,000. Blair William & Co. IL owned approximately 0.11% of Rein Therapeutics as of its most recent SEC filing.

Analyst Ratings Changes

A number of brokerages recently issued reports on RNTX. Brookline Capital Management cut Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rein Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright began coverage on Rein Therapeutics in a report on Monday, September 22nd. They issued a “buy” rating and a $10.00 target price on the stock. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $10.00.

Rein Therapeutics Trading Down 4.7%

Shares of NASDAQ:RNTX opened at $1.22 on Monday. The stock’s fifty day simple moving average is $1.22 and its two-hundred day simple moving average is $1.51. Rein Therapeutics Inc. has a 1-year low of $1.04 and a 1-year high of $4.40. The stock has a market cap of $28.43 million, a PE ratio of -0.45 and a beta of 1.14.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). On average, sell-side analysts forecast that Rein Therapeutics Inc. will post -1.56 earnings per share for the current fiscal year.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.